The Farmak* group of companies has started exporting medicines to Pakistan, which has become another important achievement within the framework of the corporate strategy “Farmak 2.0: from local to global success”. This is the second country in South Asia on the company’s export map. The first product in the new market was an injectable medication for general anesthesia, which was also registered in the UK this year.
Entering the Pakistani market was the result of the work of the Farmak International Middle East & Africa team, which is rapidly expanding the company’s presence in the region. In early December 2024, it was announced that it was entering the market of another country in the Middle East – Jordan. Success in entering new markets indicates recognition of the quality of Farmak medicines abroad and the effectiveness of work aimed at the global expansion of the Ukrainian brand.
Today, the leader of the pharmaceutical market in Ukraine** Farmak exports its own products to more than 60 countries, including 15 EU countries, as well as countries in Central and South America, the Middle East, Asia, Africa and Australia.
*The Farmak Company Group is a global pharmaceutical business, including two production facilities in Ukraine, a production facility in Spain, as well as 11 international representative offices and marketing and distribution companies in countries such as Poland, the Czech Republic, Slovakia, Great Britain, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, and Moldova. The Group’s products are exported to 60 countries, including 15 EU countries, and are manufactured in accordance with European GMP (Good Manufacturing Practice) standards.
**in terms of sales of pharmaceuticals in monetary terms, according to Proxima Research in 2023
